Acquisitions by Pfizer

  • B. Rajesh Kumar
Part of the Management for Professionals book series (MANAGPROF)


Pfizer has grown by megamergers and acquisitions. In the year 2000, Pfizer acquired Warner–Lambert. This $90-billion merger deal resulted in the creation of the second largest pharmaceutical company in the world. The deal ended the 3-month hostile battle to acquire Warner–Lambert. On merger completion, Pfizer shareholders owned approximately 61% of the new company, while Warner–Lambert shareholders owned 39% of the company. Pfizer’s acquisition of Warner–Lambert resulted in the combined group having eight products with greater than $1 billion in global sales and R&D budget which amounted to $4.7 billion. The combination gave leadership position to Pfizer in the areas of cardiovascular, lipid control drugs, central nervous system, and infectious disease pharmaceutical segments. The cumulative returns for Pfizer during the 240-day period surrounding the Warner–Lambert acquisition announcement were 29%. In 2003, Pfizer the largest drug maker bought Pharmacia for $60 billion. The merger created a drug company with $46 billion in annual sales and added portfolio of leading drugs for impotence, high cholesterol, arthritis, glaucoma, and depression. The merger consolidated position as the number one drug maker in terms of annual sales. Pfizer shareholders owned 77% of the combined company, and Pharmacia’s shareholders owned 23% of the combined company. The cumulative gains registered by the Pfizer stock on account of Pharmacia merger during the 245-day period (July 1, 2002–July 5, 2003) was 7%. During 2009, Pfizer acquired Wyeth in a cash-and-stock transaction valued at $68 billion. The combination created one of the most diversified companies in the global healthcare industry. The combination of Pfizer and Wyeth created the world’s premier biopharmaceutical company with diversification and scale position. Pfizer and Wyeth have highly complementary businesses. The cumulative returns for Pfizer accounted by Wyeth acquisition during the 251-day acquisition period (−5 to +245-day) was 16%. The average increase in operating income for Pfizer during the Wyeth post-merger 6-year period (2011–2016) was 6.5%.


  1. Hall J, Krauskopf L (2009) Pfizer to buy Wyeth for $68 billion. Accessed 23 Sept 2017
  2. Herper M (2002) Pfizer buys Pharmacia for $60 billion. Accessed 21 Sept 2017
  3. McCullagh M (2000) Data Monitor. Emerging from the Merger: Warner–Lambert and Pfizer. Accessed 19 Sept 2017
  4. Petersen M (2000) Pfizer gets its deal to buy Warner–Lambert for $90.2 billion. Accessed 18 Sept 2017
  5. Pfizer Annual Report (2017)Google Scholar
  6. Pfizer Press Release (2009) Pfizer to acquire Wyeth creating world’s premier biopharmaceutical company. https://press.pfizercom/press-release/pfizer-acquire-wyeth-creating-worlds-premier-biopharmaceutical-company. Accessed 22 Sept 2017
  7. Pfizer Website (2017b) Accessed 20 Sept 2017
  8. Report (2000) Warner–Lambert and Pfizer in a 90 billion merger deal. Accessed 18 Sept 2017
  9. Reporter (2003) It’s Official: Pfizer buys Pharmacia. Accessed 21 Sept 2017
  10. Righi G (2016) Drivers of mergers and acquisitions (M&A) in life sciences. Accessed 17 Sept 2017

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • B. Rajesh Kumar
    • 1
  1. 1.Institute of Management TechnologyDubaiUnited Arab Emirates

Personalised recommendations